Luis Fein

11.4k citations

52 papers · 3.8k indexed · 3 hit papers · h-index 18

Impact in

Cancer Research top 1%
- Breast Cancer Treatment Studies
- Cancer, Lipids, and Metabolism
Pulmonary and Respiratory Medicine top 0.5%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment

Papers in ⓘ

Oncology 34
- Cancer Treatment and Pharmacology 21
- HER2/EGFR in Cancer Research 11
- Colorectal Cancer Treatments and Studies 8
Pulmonary and Respiratory Medicine 31
- Prostate Cancer Treatment and Research 12
- Advanced Breast Cancer Therapies 7

Co-authors: Susan Feyerabend (10 shared papers)Karim Fizazi (10 shared papers)B. Yа. Alekseev (9 shared papers)Andrew Protheroe (10 shared papers)Kim N. (10 shared papers)Mustafa Özgüroğlu (9 shared papers)Nobuaki Matsubara (11 shared papers)A. Rodrı́guez-Antolı́n (10 shared papers)
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (5 papers)Cancer Research (4 papers)European Journal of Cancer (3 papers)Cancer (2 papers)
Partner nations: Argentina United States United Kingdom

In The Last Decade

Luis Fein

51 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma 2023 · 89 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 New England Journal of Medicine
2019 The Lancet Oncology
2017 New England Journal of Medicine

Peers

Countries citing papers authored by Luis Fein

Since Specialization

Citations

This map shows the geographic impact of Luis Fein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Fein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Fein more than expected).

Fields of papers citing papers by Luis Fein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Fein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Fein. The network helps show where Luis Fein may publish in the future.

Co-authors

The 25 scholars most cited alongside Luis Fein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Luis Fein Line = papers co-authored together Luis Fein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer New England Journal of Medicine ·Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre, Thian Kheoh, Youn C. Park, Mary B. Todd, Kim N. Hit paper breakdown →	2017	1413
2	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial The Lancet Oncology ·Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Giri Sulur, Yesenia Luna, Susan Li, Suneel Mundle, Kim N. Hit paper breakdown →	2019	517
3	Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial Journal of Clinical Oncology ·Manfred Kaufmann, Emilio Bajetta, Luc Dirix, Luis Fein, Stephen E. Jones, Nicoletta Zilembo, Jean-Louis Dugardyn, Cristina Nasurdi, Robert Mennel, Jožica Červek, Camilla Fowst, Anna Polli, E. Di Salle, Alexei Arkhipov, G. Piscitelli, Langdon L. Miller, Giorgio Massimini, (unknown)	2000	407
4	Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment Journal of Clinical Oncology ·E. Donnall Thomas, Henry Gómez, Rubi K. Li, Hyun Cheol Chung, Luis Fein, Valorie F. Chan, Jacek Jassem, Xavier Pivot, Judith Klimovsky, F Mendoza, Binghe Xu, Mario Campone, Guillermo Lerzo, (unknown), P. Mukhopadhyay, Linda T. Vahdat, Henri Roché	2007	383
5	Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT Journal of Clinical Oncology ·Stephen Chia, William J. Gradishar, L. Mauriac, José Bines, Frédéric Amant, Miriam Hatsue Honda Federico, Luis Fein, Gilles Romieu, Aman U. Buzdar, J.F.R. Robertson, Adam Brufsky, Kurt Possinger, Pamela Rennie, Francisco Sapunar, Elizabeth Lowe, Martine Piccart	2008	364
6	Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma New England Journal of Medicine ·Toni K. Choueiri, Thomas Powles, Laurence Albigès, Mauricio Burotto, Cezary Szczylik, Bogdan Żurawski, Eduardo Yañez Ruiz, Marco Maruzzo, Alberto Suárez Zaizar, Luis Fein, Fabio A. Schutz, Daniel Y.C. Heng, Fong Wang, Fabio Mataveli, Yu-Lin Chang, Maximiliano van Kooten Losio, Cristina Suárez, Robert J. Motzer Hit paper breakdown →	2023	89
7	Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study European Urology ·Nobuaki Matsubara, Kim N., Mustafa Özgüroğlu, A. Rodrı́guez-Antolı́n, Susan Feyerabend, Luis Fein, B. Yа. Alekseev, Giri Sulur, Andrew Protheroe, Susan Li, Suneel Mundle, Peter De Porre, NamPhuong Tran, Karim Fizazi	2019	78
8	Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma Cancer ·Carlos H. Barrios, David Hernández‐Barajas, Michael P. Brown, Se‐Hoon Lee, Luis Fein, Liu H, Hariharan Subramanian, Bridget Martell, Jinyu Yuan, Akintunde Bello, Zhixiao Wang, Rajiv Mundayat, Sun Young Rha	2011	76
9	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes Breast Cancer Research and Treatment ·Gabriel N. Hortobágyi, Henry Gómez, Rubi K. Li, Hyun Cheol Chung, Luis Fein, Valorie F. Chan, Jacek Jassem, Guillermo Lerzo, Xavier Pivot, Fernando Hurtado de Mendoza, Binghe Xu, Linda T. Vahdat, Ronald A. Peck, Pralay Mukhopadhyay, Henri Roché	2010	54
10	Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC) Supportive Care in Cancer ·Bernardo L. Rapoport, Daniel T. T. Chua, Allen Poma, Sujata Arora, Yan Wang, Luis Fein	2015	51
11	A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma Cancer ·C. Blajman, L. Balbiani, Joel A. Block, Federico Cóppola, R. Chacón, Luis Fein, S. Bonicatto, Angeles A. Alvarez, A. Schmilovich, F.M. Delgado	1999	41
12	Gallbladder cancer: surgical results after cholecystectomy in 25 patients with lamina propria invasion and 26 patients with muscular layer invasion Journal of Hepato-Biliary-Pancreatic Surgery ·Juan C. Rodríguez Otero, Amalia Proske, C Vallilengua, Marta Luján, Leonor Poletto, Stella Maris Pezzotto, Luis Fein, Jorgelina Rodríguez Otero, G Celoria	2006	28
13	VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer Annals of Oncology ·Andrew Tutt, John J. Garber, R.D. Gelber, Kelly‐Anne Phillips, Andrea Eisen, Oskar T. Johannsson, Priya Rastogi, Karen Cui, S-A. Im, R. Yerushalmi, Adam Brufsky, Maria Taboada, Giovanna Rossi, Greg Yothers, C Singer, Luis Fein, Niklas Loman, David Cameron, Christine Campbell, CE Geyer	2022	26
14	Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen European Journal of Cancer ·M. Kaufmann, Emilio Bajetta, L. Dirix, Luis Fein, Stephen E. Jones, Jožica Červek, Camilla Fowst, Anna Polli, E. Di Salle, Giorgio Massimini, G. Piscitelli	2000	25
15	Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer Annals of Oncology ·Andrew D. Seidman, Adam Brufsky, Rafat Ansari, Lowell L. Hart, Richard S. Stein, Lee S. Schwartzberg, John F. Stewart, Christy Russell, Shu‐Ching Chen, Luis Fein, Jhony A. De La Cruz‐Vargas, S.-B. Kim, José Antônio Crespo Cavalheiro, Luping Zhao, John F. Gill, Coleman K. Obasaju, Mauro Orlando, D. F. Tai	2010	23
16	Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma Lung Cancer ·Lee M. Krug, Agnieszka Woźniak, Hedy L. Kindler, Ronald Feld, Marianna Koczywas, José Luis Morero, Cristina P. Rodriguez, Helen J. Ross, Julie E. Bauman, С. В. Орлов, John C. Ruckdeschel, Alain C. Mita, Luis Fein, Xiaohui He, Robert L. Hall, Tsutomu Kawabe, S. Sharma	2014	23
17	Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer European Journal of Cancer ·Xavier Pivot, Rubi K. Li, Eva Thomas, Hyun Cheol Chung, Luis Fein, Valorie F. Chan, Jacek Jassem, Fernando Hurtado de Mendoza, Pralay Mukhopadyay, Henri Roché	2009	20
18	A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study) Clinical Breast Cancer ·Henry Gómez, Silvia P. Neciosup, C. Tosello, Max S. Mano, José Bines, Gustavo Ismael, Patrícia Xavier Santi, Hélio Pinczowski, Yeni Nerón, Marcello Ferretti Fanelli, Luis Fein, Carlos Sampaio, Guillermo Lerzo, Adolfo Capó, Juan José Zarbá, C. Blajman, Mirta Varela, Jeovany Martínez-Mesa, Gustavo Werutsky, Carlos H. Barrios	2015	19
19	LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) Annals of Oncology ·Toni K. Choueiri, Tom Powles, Laurence Albigès, M. Burotto, C. Szczylik, B. Zurawski, E. Yanez Riuz, Marco Maruzzo, Alberto Suárez Zaizar, Luis Fein, Fabio A. Schutz, Daniel Yick Chin Heng, F. Wang, Fabio Mataveli, Yih‐Leong Chang, Maximiliano van Kooten Losio, C. Suárez Rodríguez, Robert J. Motzer	2022	16
20	Exemestane Improves Survival in Metastatic Breast Cancer: Results of a Phase III Randomized Study Clinical Breast Cancer ·Manfred Kaufmann, Emilio Bajetta, Luc Dirix, Luis Fein, Stephen E. Jones, Nicoletta Zilembo, Jean-Louis Dugardyn, Cristina Nasurdi, Robert Mennel, Jožica Červek, Camilla Fowst, Anna Polli, E. Di Salle, Alexei Arkhipov, G. Piscitelli, Langdon L. Miller, Giorgio Massimini	2000	16

About Luis Fein

Luis Fein is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research and Endocrinology, Diabetes and Metabolism, having authored 52 papers that have together received 3.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (21 papers), Prostate Cancer Treatment and Research (12 papers), HER2/EGFR in Cancer Research (11 papers), Radiopharmaceutical Chemistry and Applications (10 papers), Colorectal Cancer Treatments and Studies (8 papers), Advanced Breast Cancer Therapies (7 papers), Breast Cancer Treatment Studies (5 papers) and Hormonal and reproductive studies (5 papers). The work is most often cited by research in Cancer Research (1.3k citations), Pulmonary and Respiratory Medicine (2.6k citations), Oncology (1.7k citations), Radiology, Nuclear Medicine and Imaging (727 citations) and Endocrinology, Diabetes and Metabolism (427 citations). Luis Fein has collaborated with scholars based in Argentina, United States and United Kingdom. Frequent co-authors include Susan Feyerabend, Karim Fizazi, B. Yа. Alekseev, Andrew Protheroe, Kim N., Mustafa Özgüroğlu, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, Dingwei Ye and Peter De Porre. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Cancer and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact